Barclays PLC Raises Position in Akoya Biosciences, Inc. (NASDAQ:AKYA)

Barclays PLC grew its holdings in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 320.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,472 shares of the company’s stock after purchasing an additional 30,095 shares during the period. Barclays PLC’s holdings in Akoya Biosciences were worth $107,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Street Corp lifted its holdings in shares of Akoya Biosciences by 4.2% during the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after purchasing an additional 18,361 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after acquiring an additional 144,903 shares during the period. Bank of New York Mellon Corp increased its position in shares of Akoya Biosciences by 16.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after acquiring an additional 9,429 shares during the period. Finally, Regal Investment Advisors LLC increased its position in shares of Akoya Biosciences by 64.3% in the 2nd quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after acquiring an additional 7,340 shares during the period. Hedge funds and other institutional investors own 79.42% of the company’s stock.

Akoya Biosciences Price Performance

Shares of AKYA opened at $3.23 on Friday. The business’s 50-day moving average is $2.45 and its two-hundred day moving average is $2.58. The company has a market capitalization of $160.11 million, a P/E ratio of -2.74 and a beta of 1.18. The company has a debt-to-equity ratio of 5.62, a quick ratio of 1.85 and a current ratio of 2.75. Akoya Biosciences, Inc. has a fifty-two week low of $1.88 and a fifty-two week high of $6.31.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AKYA shares. Canaccord Genuity Group downgraded Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of Akoya Biosciences in a research report on Tuesday, November 19th. Finally, Craig Hallum downgraded Akoya Biosciences from a “buy” rating to a “hold” rating and cut their target price for the company from $7.00 to $5.00 in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Akoya Biosciences currently has a consensus rating of “Hold” and a consensus price target of $5.43.

Akoya Biosciences Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.